Scroll down to see a list of videos and posts about Tresiba basal insulin.
Tresiba is to basal insulins what Afrezza is to mealtime insulin. Previously, Type 1 diabetics had to be attached to a pump to deliver a relatively stable rate of basal insulin. The injectable long-acting insulin analogues each came with compromises that have a huge impact on the quality of life of a diabetic.
Tresiba promises a huge improvement over previous basals, without the inconvenience of a pump:
Convenient dosing – once-daily, anytime. Missing a train can ruin your glucose levels with lengthy follow-on effects with Levemir. And if you stay out late or crash at a friends house you’ve got the same problem with Toujeo. Can Tresiba really let you dose anytime each day?
The flattest profile of basals. No sudden peaks and no troughs should make it very predictable and easier to use than Levemir. But is this always a strength? How does it cope with periods of physical activity?
Day-to-day consistency. The mechanism for Tresiba’s slow release works the same every day. Unlike the variable Lantus and Toujeo, which can unexpectedly release high levels of insulin at random intervals, causing hypoglycaemia.
Less m-cresol and phenol. Many diabetics are concerned about m-cresol used in injectable insulins (here and here). Levemir also contains phenol. Tresiba gives less than half the daily dose of m-cresol compared to Lantus or Levemir, along halving the phenol dose of Levemir. In addition, Tresiba 200 is available which further halves both phenol and m-cresol.
The maker of Tresiba seems to be understating the capabilities of the product, which is leaving the early adopters very impressed. In fact, the trials of Tresiba showed that it works almost as well when used just three times a week!
Although Tresiba is available in many countries across the globe, it isn’t yet available in Australia or Canada. However it is now available in the US and hopefully it shouldn’t be too long before it is more widely available.
Posts about Tresiba insulin (newest first):